What is vTv Therapeutics Inc?
, a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 78.99M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.